Pharmacyclics Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
PHARMACYCLICS INC has two approved drugs.
There are forty US patents protecting PHARMACYCLICS INC drugs.
There are two hundred and ninety-one patent family members on PHARMACYCLICS INC drugs in forty-two countries and thirty-four supplementary protection certificates in fifteen countries.
Summary for Pharmacyclics Inc
| International Patents: | 291 |
| US Patents: | 40 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 9,795,604 | See Plans and Pricing | See Plans and Pricing | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | 8,008,309 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 10,463,668 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
International Patents for Pharmacyclics Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1129274 | See Plans and Pricing |
| European Patent Office | 2526934 | See Plans and Pricing |
| Poland | 2526933 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2201840 | PA2015017,C2201840 | Lithuania | See Plans and Pricing | PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2526934 | 93321 | Luxembourg | See Plans and Pricing | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 - IMBRUVICA - IBRUTINIB |
| 2201840 | 92692 | Luxembourg | See Plans and Pricing | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
